[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"intraventricular-conduction-delay\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:intraventricular-conduction-delay":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100489249","left-vs-left-randomized-clinical-trial-100489249",false,"NCT05650658","Left vs Left Randomized Clinical Trial","Cardiac Resynchronization Therapy Using His\u002FLeft Bundle Branch Pacing vs Biventricular Pacing With a Left Ventricular Epicardial Lead in Patients With Heart Failure (HF) With Left Ventricular Ejection Fraction (LVEF)≤50% and With Either a Wide QRS Complex (>130 ms) or With\u002FAnticipated >40% Pacing Randomized Clinical Trial","Inclusion Criteria:\n\n* Men and women 18 years of age or older.\n* A LVEF ≤ 50% within 6 months prior to enrollment.\n* Resting QRS duration ≥130 ms as evidenced by a historical 12-lead ECG prior to enrollment OR anticipated right ventricular pacing \\>40% OR device in place with right ventricular pacing \\> 40%.\n* Are optimized on HF guideline directed medical therapy according to current HF published guidelines OR patient's physician will make an effort to start all guideline-directed medical therapy and titrate doses up as permitted by the participant clinical status and co-morbidities prior to implantation procedure.\n\nExclusion Criteria:\n\n* Women who are pregnant, lactating, or plan to become pregnant during the course of the trial.\n* Participants with angiographic evidence of coronary disease who are candidates for coronary revascularization and are likely to undergo coronary artery bypass graft surgery or percutaneous coronary, intervention in the next three (3) months.\n* Enzyme-positive myocardial infarction within the past three (3) months prior to enrollment.\n* Coronary artery bypass graft surgery or percutaneous coronary intervention (balloon and\u002For stent angioplasty) within the past three (3) months prior to enrollment.\n* Reversible non-ischemic cardiomyopathy (e.g., acute viral myocarditis).\n* Participants with Chagas disease, cardiac sarcoidosis or amyloidosis.\n* Expected to receive left ventricular assist device or heart transplantation within 6 months.\n* Participants with primary severe valvular disease (e.g., aortic stenosis).\n* Have a life expectancy of less than 12 months.\n* Participants with irreversible brain damage from preexisting cerebral disease.\n* Participants with a contrast dye allergy unable or unwilling to undergo pretreatment with steroids and\u002For diphenhydramine.\n* Participants participating in any other interventional cardiovascular clinical trial.\n* Participants who would be unable to comply with the study's follow-up visit schedule; or\n* Participants who had any prior unsuccessful attempt at implantation of biventricular pacing (BiVP), His Bundle Pacing (HBP), or Left Bundle Branch Pacing (LBBP) device.","ALL","18 Years",{"count":19,"type":20},2136,"ESTIMATED","INTERVENTIONAL",[23],"NA","The investigators aim to prospectively test the comparative effectiveness of His or Left bundle branch pacing in relation to patient centered outcomes (quality of life, physical activity, heart failure hospitalization, mortality) and comparative safety in relation to device-related complications and re-interventions (e.g., lead dislodgement, infection) relative to standard of care biventricular pacing in patients with heart failure due to left ventricular systolic dysfunction (LVEF≤50%) and with either a wide QRS (≥130 ms) or with\u002Fanticipated \\>40% pacing who are already receiving current standard heart failure pharmacological therapy.",[26,27,28,29,30,31,32],"Heart Failure","Heart Failure With Reduced Ejection Fraction","AV Block","LBBB","RBBB","Intraventricular Conduction Delay","Pacing-Induced Cardiomyopathy","RECRUITING","2025-09-28",{"date":36,"type":37},"2025-10-02","ACTUAL",{"date":39,"type":37},"2023-09-13",{"date":41,"type":20},"2029-06-30",{"name":43,"class":44},"Baylor College of Medicine","OTHER",71,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":21,"phases":56,"briefSummary":57,"conditions":58,"keywords":62,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":78},"100597365","uhf-ecg-in-lbbb-and-response-to-crt-prediction-100597365","NCT07057544","UHF ECG in LBBB and Response to CRT Prediction","The Role of Ultra-high-frequency ECG in the Localization of Left Ventricular Conduction Disorders and Prediction of Response to Resynchronization Therapy","UHF BLOCK","Inclusion Criteria:\n\n* HF due to ischemic or non-ischemic cardiomyopathy\n* known coronary angiography\n* NYHA II-IV\n* LVEF ≤40%\n* non-RBBB QRSd lasting \\>130 ms (by automated measurement)\n* proximal LBBB proved by an invasive EP study or non-invasive dyssynchrony assessment in case such a method is confirmed to be non-inferior to an invasive EP study during the project\n\nExclusion Criteria:\n\n* Age ˂18 years\n* heart failure from reversible causes\n* Moderate to severe aortic stenosis\n* pregnancy\n* active myocarditis\n* hypertrophic cardiomyopathy\n* cardiac valve surgery in the last three months\n* myocardial infarction, PCI, or CABG in the last three months\n* severe valvular disease requiring intervention\n* severe atherosclerotic disease of the aorta and\u002For femoral arteries\n* life expectancy ˂1 year\n* known medical condition or contraindication causing potential complications for EP study",{"count":55,"type":20},200,[23],"The main objective of the project is to demonstrate that in patients with heart failure and QRS complex of nonRBBB morphology lasting over 130 ms, UHF-ECG can differentiate patients with trueLBBB from IVCD better than existing approaches based on the assessment of QRS complex morphology and duration from 12-lead ECG.\n\nAnother goal of the proposed study is to demonstrate that trueLBBB patients will benefit more from CRT using left bundle branch pacing than from CRT using biventricular pacing.\n\nThe final aim of the project is to demonstrate that the echocardiographic and clinical response in patients with intraventricular conduction disturbance will be dependent on the degree of reduction in ventricular dyssynchrony after CRT.",[59,60,61,31],"Left Bundle Branch Block","Left Bundle Branch Area Pacing","Biventricular Pacing",[63,64,65,66,67],"left bundle branch block","resynchronization therapy","intraventricular conduction delay","left bundle branch pacing","biventricular pacing","2025-07-09",{"date":70,"type":37},"2025-07-14",{"date":72,"type":37},"2024-05-01",{"date":74,"type":20},"2027-12-31",{"name":76,"class":77},"Faculty Hospital Kralovske Vinohrady","OTHER_GOV",1]